Study of SHR-1701 Plus BP102 in Subjects With Selected Solid Tumors

Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer Clinical Trial

Official title: A Multicenter, Open-Label, Phase Ib/II Trial of SHR-1701 Plus BP102 in Subjects With Selected Solid Tumors

Status Not yet recruiting

Clinical Trial Summary

The main purpose of this study was to assess the safety,efficacy and pharmacokinetic when combining SHR-1701 and BP102 in participants with advanced or metastatic non-squamous non-small cell lung cancer. To explore the immunogenicity of SHR-1701 and the relationship between corresponding biomarkers and therapeutic effect.

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• Carcinoma, Non-Small-Cell Lung

• NCT number: NCT04974957
• Study type: Interventional
• Source: Suzhou Suncadia Biopharmaceuticals Co., Ltd.
• Contact: Hao Shen
• Phone: +0518-82342973
• Email: hao.shen@hengrui.com
• Status: Not yet recruiting
• Phase: Phase 2
• Start date: August 30, 2021
• Completion date: August 30, 2022